Agreements

Date: 2017-06-16

Type of information: Licensing agreement

Compound: low molecular weight peptidomimetic of human nerve growth factor (NGF) ((1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine)

Company: Recordati (Italy) Mimetech (Italy)

Therapeutic area: Rare diseases - Ophtalmological diseases

Type agreement: licensing - development - commercialisation

Action mechanism: peptide.

Disease: neurotrophic keratitis

Details:

•  • On June 16, 2017, Recordati announced the signing of an exclusive license agreement with MimeTech, an Italian development stage company founded by scientists from the University in Florence, for the development and subsequent commercialization on a global basis of a low molecular weight peptidomimetic of human nerve growth factor (NGF) for the treatment of neurotrophic keratitis, which already received an orphan drug designation in the EU.
• Additional indications linked to NGF defects are also contemplated in the scope of the partnership.

Financial terms: Under the terms of the agreement Recordati shall make an upfront payment upon signature of the contract and further milestone payments shall be linked to the development process and commercial performance.

Latest news:

Is general: Yes